[144] Biogen Inc. SEC Filing

Rhea-AI Filing Summary

Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.

The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.

Insights

Financial Analyst

TL;DR Small executive/insider sale of newly vested restricted shares; dollar size is modest relative to outstanding equity.

The filing documents a proposed sale of 517 shares valued at $69,045.35 arising from restricted stock vesting and designated as compensation. The sale is to occur through Fidelity on NASDAQ and there are 146,614,598 shares outstanding, so the stake being sold is immaterial to capitalization. No prior sales in the past three months are reported. From a financial-materiality standpoint, this transaction is routine and unlikely to affect company valuation or market dynamics.

Corporate Governance Expert

TL;DR Standard Rule 144 notice for vested compensation; disclosure and representations align with regulatory requirements.

The Form 144 attributes the shares to restricted stock vesting and notes compensation as the payment nature, which is consistent with typical insider compensation mechanics. The filer makes the required representation of no undisclosed material adverse information. The document contains broker details and an approximate sale date. There are no indications of unusual arrangements, aggregated prior sales, or reliance on a trading plan in this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	517	69045.35	146614598	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Restricted Stock Vesting	Issuer			517	09/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the BIIB Form 144 cover?

The notice covers 517 shares of Biogen common stock.

What is the aggregate market value of the shares in the BIIB filing?

The filing reports an aggregate market value of $69,045.35 for the 517 shares.

How were the shares acquired according to the Form 144?

The shares were acquired on 09/01/2025 through restricted stock vesting from the issuer and the payment is listed as compensation.

When is the approximate sale date and through which broker will the BIIB shares be sold?

The approximate sale date is 09/02/2025 and the broker listed is Fidelity Brokerage Services LLC.

Does the filing report any securities sold by the filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.